一项评估 TAR-210 与单药膀胱内癌症治疗对膀胱癌患者的研究 (MoonRISe-1)
一项 3 期随机研究,评估 TAR-210 Erdafitinib 膀胱内给药系统与单药膀胱内化疗在中危非肌层浸润性膀胱癌 (IR-NMIBC) 和易感 FGFR 改变的受试者中的疗效和安全性
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
学习地点
-
-
-
Beijing、中国、100191
- 主动,不招人
- Peking University Third Hospital
-
Beijing、中国、100050
- 主动,不招人
- Beijing Friendship Hospital Capital Medical University
-
Changsha、中国、410013
- 主动,不招人
- Hunan Cancer hospital
-
Chengdu、中国、610041
- 主动,不招人
- West China School of Medicine/West China Hospital, Sichuan University
-
Chengdu、中国、610014
- 主动,不招人
- The Third People's Hospital of Chengdu
-
Chongqing、中国、400033
- 主动,不招人
- Chongqing Cancer Hospital
-
Fuzhou、中国、350001
- 主动,不招人
- Fujian Medical University Union Hospital
-
Guangzhou、中国、510060
- 主动,不招人
- Sun Yat Sen University Cancer Center
-
Nanjing、中国、210008
- 主动,不招人
- Nanjing Drum Tower Hospital
-
Nanjing、中国、210009
- 主动,不招人
- Zhongda Hospital Southeast University
-
Shanghai、中国、200031
- 主动,不招人
- Huadong Hospital Affiliated to Fudan University
-
Tianjin、中国、300061
- 主动,不招人
- The Second Hospital Of Tianjin Medical University
-
Wenzhou、中国、325000
- 主动,不招人
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan、中国、430032
- 主动,不招人
- Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Xinshi、中国、710063
- 主动,不招人
- The First Affiliated Hospital of Xian Jiaotong University
-
Xuzhou、中国、221004
- 主动,不招人
- The Affiliated Hospital of Xuzhou Medical University
-
Ürümqi、中国、830011
- 主动,不招人
- Cancer Hospital of Xinjiang Medical University
-
-
-
-
-
Aarhus、丹麦、8200
- 招聘中
- Aarhus University Hospital
-
Copenhagen、丹麦、2100
- 招聘中
- Rigshospitalet
-
Herlev、丹麦、2730
- 招聘中
- Herlev Hospital
-
Odense、丹麦、5000
- 招聘中
- Odense Universitetshospital
-
Roskilde、丹麦、4000
- 招聘中
- Zealand University Hospital
-
-
-
-
-
Haifa、以色列、3109601
- 招聘中
- Rambam Health Care Campus
-
Ramat Gan、以色列、52621
- 招聘中
- Sheba Medical Center
-
Sderot、以色列、13100
- 招聘中
- Ziv Medical Center
-
Tel Aviv、以色列、6423906
- 招聘中
- Sourasky Medical Center
-
Yeruham、以色列、9112001
- 完全的
- Hadassah University Hospita Ein Kerem
-
-
-
-
-
?zmir、土耳其(türkiye)、35330
- 招聘中
- Dokuz Eylul University Medical Faculty
-
Adana、土耳其(türkiye)、01120
- 完全的
- Adana Baskent Practice and Research Hospital
-
Ankara、土耳其(türkiye)、06200
- 招聘中
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara、土耳其(türkiye)、06100
- 完全的
- Ankara University Medical Faculty
-
Istanbul、土耳其(türkiye)、34722
- 招聘中
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul、土耳其(türkiye)、34153
- 完全的
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul、土耳其(türkiye)、34865
- 招聘中
- Kartal Dr Lutfi Kirdar sehir Hastanesi
-
-
-
-
-
Graz、奥地利、8036
- 招聘中
- Medizinische Universitaet Graz
-
Innsbruck、奥地利、6020
- 招聘中
- Medizinische Universitat Innsbruck
-
Leopoldsdorf (Wien)、奥地利、1090
- 招聘中
- Medical University Vienna MUV
-
Linz、奥地利、4020
- 招聘中
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg、奥地利、5020
- 招聘中
- Universitaetsklinikum Salzburg Landeskrankenhaus
-
-
-
-
-
Barretos、巴西、14780-070
- 主动,不招人
- Fundacao Pio XII
-
Campinas、巴西、13083-888
- 完全的
- Universidade Estadual De Campinas
-
Natal、巴西、59062 000
- 主动,不招人
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、巴西、90035-001
- 主动,不招人
- Hospital Moinhos de Vento
-
Porto Alegre、巴西、90050 170
- 主动,不招人
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Salvador、巴西、41810-011
- 主动,不招人
- HBA SA Assitencia Medica e Hospitalar
-
Santo André、巴西、09060-650
- 主动,不招人
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo、巴西、01246-000
- 主动,不招人
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo、巴西、01509 900
- 完全的
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、巴西、01221-020
- 主动,不招人
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo、巴西、01323 900
- 主动,不招人
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Berlin、德国、10117
- 主动,不招人
- Charite - Universitaetsmedizin Berlin (CCM)
-
Braunschweig、德国、38126
- 招聘中
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Cologne、德国、50968
- 招聘中
- Studienzentrum Bayenthal
-
Dresden、德国、01307
- 完全的
- Urologische Gemeinschaftspraxis
-
Frankfurt am Main、德国、60596
- 招聘中
- Universitaetsklinikum Frankfurt
-
Hamburg、德国、22081
- 主动,不招人
- Urologikum Hamburg MVZ - Germany
-
Herne、德国、44625
- 招聘中
- Marien hospital Herne
-
Jena、德国、07747
- 主动,不招人
- Universitatsklinikum Jena
-
München、德国、81675
- 完全的
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Straubing、德国、94315
- 招聘中
- Klinikum St. Elisabeth Straubing GmbH
-
Stuttgart、德国、70174
- 完全的
- Katharinenhospital Innere Medizin
-
-
-
-
-
Arezzo、意大利、52100
- 招聘中
- Ospedale S. Donato Arezzo, USL 8 - U.O. Oncologia Medica
-
Bergamo、意大利、24125
- 招聘中
- Cliniche Humanitas Gavazzeni
-
Brescia、意大利、25123
- 招聘中
- ASST Spedali Civili Brescia
-
Milan、意大利、20133
- 招聘中
- Istituto Dei Tumori Di Milano
-
Milan、意大利、20132
- 完全的
- Ospedale San Raffaele
-
Romagnano、意大利、00128
- 招聘中
- Universita Campus Bio-Medico di Roma
-
Romagnano、意大利、00144
- 招聘中
- Istituto Nazionale Tumori Regina Elena
-
Rozzano、意大利、20089
- 招聘中
- Istituto Clinico Humanitas
-
Torino、意大利、10126
- 招聘中
- A.O.Citta della Salute e della Scienza di Torino
-
-
-
-
-
Hradec Králové、捷克语、500 05
- 完全的
- Fakultni nemocnice Hradec Kralove
-
Olomouc、捷克语、779 00
- 招聘中
- Fakultni nemocnice Olomouc
-
Prague、捷克语、128 08
- 招聘中
- Vseobecna fakultni nemocnice v Praze
-
Prague、捷克语、150 06
- 招聘中
- Fakultni nemocnice v Motole
-
Prague、捷克语、140 59
- 招聘中
- Fakultni Thomayerova nemocnice
-
-
-
-
-
Amagasaki、日本、660 8550
- 主动,不招人
- Hyogo Prefectural Amagasaki General Medical Center
-
Kawasaki、日本、216 8511
- 招聘中
- St Marianna University Hospital
-
Kobe、日本、650 0047
- 主动,不招人
- Kobe City Medical Center General Hospital
-
Kumamoto、日本、860 0008
- 主动,不招人
- National Hospital Organization Kumamoto Medical Center
-
Osaka、日本、541 8567
- 招聘中
- Osaka International Cancer Institute
-
Saitama、日本、350 8550
- 主动,不招人
- Saitama Medical Center
-
Wakayama、日本、640 8558
- 主动,不招人
- JRC Wakayama Medical Center
-
Yokohama、日本、221 0855
- 招聘中
- Yokohama Municipal Citizen's Hospital
-
Yokohama、日本、232 0024
- 主动,不招人
- Yokohama City University Medical Center
-
Yokosuka、日本、238 8558
- 招聘中
- Yokosuka Kyosai Hospital
-
Ōta-ku、日本
- 招聘中
- Gunma Prefectural Cancer Center
-
-
-
-
-
Aalst、比利时、9300
- 招聘中
- AZORG campus Aalst Moorselbaan
-
Brugge (Bruges)、比利时、8000
- 招聘中
- AZ Sint-Jan
-
Edegem、比利时、2650
- 完全的
- UZ Antwerpen
-
Gent (Ghent)、比利时、9000
- 招聘中
- AZ Maria Middelares
-
Leuven、比利时、3000
- 主动,不招人
- Universitair Ziekenhuis Gasthuisberg
-
Sint-Niklaas、比利时、9100
- 招聘中
- Vitaz
-
Yvoir、比利时、5530
- 招聘中
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Lille、法国、59000
- 完全的
- Hospital Center University De Lille
-
Limoges、法国、87000
- 招聘中
- Polyclinique de Limoges - Francois Chenieux
-
Lyon、法国、69003
- 招聘中
- Hôpital Edouard Herriot
-
Marseille、法国、13009
- 招聘中
- Institut Paoli Calmettes
-
Paris、法国、75010
- 招聘中
- Hopital Saint Louis
-
Paris、法国、75013
- 招聘中
- CHU Pitie Salpetriere
-
Paris、法国、75018
- 招聘中
- APHP - Hopital Bichat - Claude Bernard
-
Quint-Fonsegrives、法国、31130
- 招聘中
- Clinique de la Croix du Sud
-
Rennes、法国、35000
- 完全的
- Chu Rennes Hopital Pontchaillou
-
Toulouse、法国、31059
- 招聘中
- CHU Rangueil
-
Villejuif、法国、94805
- 招聘中
- Institut Gustave Roussy
-
-
-
-
-
Bialystok、波兰、15 276
- 主动,不招人
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz、波兰、85 048
- 主动,不招人
- IN VIVO Sp. z o.o
-
Bydgoszcz、波兰、85 796
- 完全的
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Lublin、波兰、20 090
- 主动,不招人
- Uniwersytecki Szpital Kliniczny nr 4
-
Przemyśl、波兰、37 700
- 主动,不招人
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
-
Tarnów、波兰、33-100
- 主动,不招人
- Szpital Wojewodzki Im Sw Lukasza Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Tarnowie
-
Torun、波兰、87-100
- 完全的
- Medicover Integrated Clinical Services Sp z o o
-
Wiele、波兰、05-135
- 主动,不招人
- Mazowiecki Szpital Onkologiczny Sp z o o
-
Wroclaw、波兰、50 981
- 完全的
- 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
-
Wroclaw、波兰、53-413
- 主动,不招人
- Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
-
-
-
-
-
Cork、爱尔兰、T12 DC4A
- 主动,不招人
- Cork University Hospital
-
Dublin、爱尔兰、D07 A8NN
- 主动,不招人
- Mater Misericordiae University Hospital
-
Dublin、爱尔兰、D07 WKW8
- 主动,不招人
- Mater Private Hospital
-
Dublin、爱尔兰、D24 NR0A
- 主动,不招人
- Adelaide and Meath Hospital
-
-
-
-
Arkansas
-
Little Rock、Arkansas、美国、72211
- 完全的
- Arkansas Urology
-
-
California
-
Los Alamitos、California、美国、90720
- 主动,不招人
- Genesis Research LLC
-
Los Angeles、California、美国、90033
- 主动,不招人
- USC Norris Comprehensive Cancer Center
-
Orange、California、美国、92868
- 主动,不招人
- University of California Irvine Medical Center
-
San Diego、California、美国、92123
- 主动,不招人
- Om Research LLC
-
Sherman Oaks、California、美国、91411
- 完全的
- Genesis Research LLC 1
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 完全的
- University of Colorado Cancer Center Anschultz Cancer Pavilion
-
Lakewood、Colorado、美国、80228
- 主动,不招人
- Colorado Clinical Research
-
San Luis、Colorado、美国、63141
- 完全的
- Mercy Research
-
San Luis、Colorado、美国、63141
- 主动,不招人
- Specialty Clinical Research of St Louis
-
-
Florida
-
Tampa、Florida、美国、33612
- 主动,不招人
- Moffitt Cancer Center
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 完全的
- Northwestern University
-
-
Indiana
-
Jeffersonville、Indiana、美国、47130
- 完全的
- First Urology
-
-
Kansas
-
Wichita、Kansas、美国、67226
- 主动,不招人
- Wichita Urology Group
-
-
Louisiana
-
New Orleans、Louisiana、美国、70121-2429
- 主动,不招人
- Ochsner Health System
-
-
Maryland
-
Hanover、Maryland、美国、21076
- 完全的
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 完全的
- Brigham And Women's Hospital
-
-
Michigan
-
Detroit、Michigan、美国、48201
- 主动,不招人
- Karmanos Cancer Institute
-
Royal Oak、Michigan、美国、48073
- 主动,不招人
- Comprehensive Urology
-
-
Nebraska
-
Omaha、Nebraska、美国、68114
- 主动,不招人
- The Urology Center, PC
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08901
- 主动,不招人
- Cancer Institute Of New Jersey
-
-
New York
-
New York、New York、美国、10065
- 主动,不招人
- Memorial Sloan Kettering Cancer Center
-
New York、New York、美国、10016
- 完全的
- Integrated Medical Professionals
-
Syracuse、New York、美国、13210
- 主动,不招人
- SUNY Upstate Med Univ
-
Syracuse、New York、美国、13210
- 主动,不招人
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- 主动,不招人
- Levine Cancer Institute
-
Raleigh、North Carolina、美国、27612
- 主动,不招人
- Associated Urologists of North Carolina
-
-
Pennsylvania
-
Bala-Cynwyd、Pennsylvania、美国、19004
- 完全的
- MidLantic Urology
-
Lancaster、Pennsylvania、美国、17604
- 主动,不招人
- Keystone Urology Specialists
-
-
South Carolina
-
Myrtle Beach、South Carolina、美国、29572
- 主动,不招人
- Carolina Urologic Research Center
-
-
Tennessee
-
Germantown、Tennessee、美国、38138
- 主动,不招人
- The Conrad Pearson Clinic
-
Knoxville、Tennessee、美国、37920
- 完全的
- University of Tennessee Medical Center
-
Nashville、Tennessee、美国、37209
- 主动,不招人
- Urology Associates
-
-
Texas
-
Austin、Texas、美国、78745
- 主动,不招人
- Urology Austin
-
Dallas、Texas、美国、75231
- 主动,不招人
- Urology Clinics of North Texas
-
Dallas、Texas、美国、75390
- 完全的
- UT Southwestern
-
Houston、Texas、美国、77027
- 主动,不招人
- Houston Metro Urology
-
-
Washington
-
Spokane、Washington、美国、99202
- 主动,不招人
- Spokane Urology
-
-
-
-
-
Bristol、英国、BS105NB
- 主动,不招人
- Southmead Hospital
-
London、英国、W6 8RF
- 主动,不招人
- Charing Cross Hospital
-
London、英国、EC1A 7BE
- 主动,不招人
- St Bartholomews Hospital
-
Newcastle upon Tyne、英国、NE7 7DN
- 主动,不招人
- Newcastle Freeman Hospital
-
Sheffield、英国、S10 2SJ
- 主动,不招人
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Southampton、英国、SO16 6YD
- 主动,不招人
- Southampton General Hospital
-
Sutton、英国、SM2 5PT
- 主动,不招人
- Royal Marsden Hospital
-
-
-
-
-
Alzira、西班牙、46600
- 招聘中
- Hosp. Univ. de La Ribera
-
Barcelona、西班牙、08025
- 招聘中
- Fund. Puigvert
-
Barcelona、西班牙、08036
- 招聘中
- Hosp Clinic de Barcelona
-
Barcelona、西班牙、08035
- 完全的
- Hosp Univ Vall D Hebron
-
Cadiz、西班牙、11009
- 招聘中
- Hosp. Puerta Del Mar
-
Castillón、西班牙、12004
- 招聘中
- Hosp. Gral. Univ. de Castellon
-
Jerez de la Frontera、西班牙、11407
- 招聘中
- Hosp. de Jerez de La Frontera
-
La Coruña (A Coruña)、西班牙、15006
- 招聘中
- Hosp Univ A Coruna
-
Madrid、西班牙、28041
- 招聘中
- Hosp. Univ. 12 de Octubre
-
Madrid、西班牙、28027
- 招聘中
- Clinica Univ. de Navarra
-
Madrid、西班牙、28007
- 完全的
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga、西班牙、29010
- 招聘中
- Hosp Virgen de La Victoria
-
Oviedo、西班牙、33011
- 完全的
- Hosp. Univ. Central de Asturias
-
Sabadell、西班牙、08208
- 招聘中
- Hosp.Univ.Parc Tauli
-
Seville、西班牙、41013
- 完全的
- Hosp. Virgen Del Rocio
-
Valencia、西班牙、46010
- 招聘中
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Buenos Aires、阿根廷、C1419AHN
- 主动,不招人
- Hospital Sirio Libanes
-
Chabas、阿根廷、C1425
- 主动,不招人
- Investigaciones Clinico Moleculares (ICM)
-
Córdoba、阿根廷、5000
- 主动,不招人
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba、阿根廷、X5000KPH
- 主动,不招人
- Centro Urologico Profesor Bengio
-
Mar del Plata、阿根廷、B7602
- 主动,不招人
- Hospital Privado de la Comunidad
-
Rosario、阿根廷、2000
- 主动,不招人
- Sanatorio de la Mujer
-
-
-
-
-
Chuncheon、韩国、28644
- 完全的
- Chungbuk National University Hospital
-
Gyeongin、韩国、10408
- 招聘中
- National Cancer Center
-
Sangam-dong、韩国、58128
- 招聘中
- Chonnam National University Hwasun Hospital
-
Seoul、韩国、06351
- 招聘中
- Samsung Medical Center
-
Seoul、韩国、3080
- 招聘中
- Seoul National University Hospital
-
Seoul、韩国、06591
- 主动,不招人
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Hong Kong、香港
- 主动,不招人
- Queen Mary Hospital
-
Hong Kong、香港
- 主动,不招人
- Prince Of Wales Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Main study only: Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteria fulfilled: a. Ta low grade (LG)/ Grade 1 (G1): primary or recurrent, b. Ta LG/G2: primary or recurrent and c. Greater than or equal to (>=) 1 of the following risk factors: i. Multiple Ta LG tumors, ii. Solitary LG tumor >= 3 cm, iii. Early recurrence (less than [<] 1 year), iv. Frequent recurrence (greater than [>] 1 per year), v. Recurrence after prior adjuvant intravesical treatment (single perioperative dose of chemotherapy does not fulfill this risk factor)
- Substudy only: Have a histologically confirmed new diagnosis (within 90 days of randomization) of IR-NMIBC for whom MMC is deemed the therapy of choice according to local standard of care with at least 1 of the following criteria fulfilled: a. Ta LG/G1, b. Ta LG/G2, and >=1 of the following risk factors: i) Multiple Ta LG tumors, ii) Solitary LG tumor >=3 cm
- Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
- Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence/progression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm.
- Visible papillary disease must be fully resected prior to randomization and absence of disease must be documented at Screening cystoscopy
- Can have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Have an Eastern Cooperative Oncology Group performance status of 0 to 2
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients, including: a. Erdafitinib excipients; b.TAR-210 drug delivery system constituent materials ; c. urinary placement catheter materials; d. MMC or chemically related drugs; e. Gemcitabine or chemically related drugs
- Presence of any bladder or urethral anatomic feature (that is, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-210 or passage of a urethral catheter for intravesical chemotherapy
- Polyuria with recorded 24-hour urine volumes > 4000 milliliters (mL)
- Current indwelling urinary catheters, however, intermittent catheterization is acceptable
- Had major surgery or had significant traumatic injury and/or not fully recovered within 4 weeks before first dose (TURBT is not considered major surgery)
Substudy:
- Previous diagnosis of histologically confirmed urothelial bladder carcinoma at any time prior to current qualifying diagnosis
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Main Study: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
其他名称:
|
|
有源比较器:Main Study: Group B: MMC or Gemcitabine
Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
Gemcitabine will be administered intravesically. MMC will be administered intravesically. |
|
实验性的:Substudy: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
其他名称:
|
|
有源比较器:Substudy: Group B: MMC
Participants in substudy Group B will receive intravesical MMC once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
MMC will be administered intravesically. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease Free Survival (DFS)
大体时间:From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first. |
From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to next Treatment (TTNT)
大体时间:From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
TTNT is measured as the time from randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer. |
From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
|
High Grade Recurrence-free Survival (HG RFS)
大体时间:From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
HG RFS is measured as the time from randomization to the date of first documented evidence of HG NMIBC or death, whichever occurs first |
From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
|
Progression Free Survival (PFS)
大体时间:From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
PFS is measured as the time from randomization to the date of first documented evidence of disease progression or death, whichever occurs first. |
From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
|
Number of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment
大体时间:From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
Number of diagnostic and therapeutic invasive urological interventions after study treatment, that is, endoscopic procedures (e.g., cystoscopies, transurethral resection of bladder tumors (TURBTs), ureteroscopies, urethral interventions, urethral stricture/bladder neck incision), catheterization (intravesical, suprapubic), intravesical treatments, major surgeries (e.g., radical cystectomy, simple cystectomy, urethroplasty) will be reported. |
From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
|
Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities)
大体时间:From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
An AE is any untoward medical occurrence in a participant participating in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product, that does not necessarily have a causal relationship with the treatment. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening and Grade 5: Death. Number of participants with adverse events (including physical examination, vital signs and laboratory abnormalities) will be reported. |
From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
|
Overall Survival (OS)
大体时间:From randomization to the date of death (approximately 4 years and 2 months)
|
OS is defined as the time from randomization to the date of death from any cause. |
From randomization to the date of death (approximately 4 years and 2 months)
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores
大体时间:Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores
大体时间:Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores
大体时间:Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the HRQoL of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores
大体时间:Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
合作者和调查者
调查人员
- 研究主任:Johnson & Johnson Enterprise Innovation Inc. Clinical Trial、Johnson & Johnson Enterprise Innovation Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 42756493BLC3004
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.